Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Intravenous brentuximab vedotin (ADCETRIS
®
) is a targeted antibody-drug conjugate (ADC) active against CD30-positive cancer cells such as those associated with classical Hodgkin lymphoma (HL). In noncomparative, phase 2 trials and in the real-world setting, salvage therapy with brentuximab vedotin resulted in high objective response (comple...
Alternative Titles
Full title
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7102329
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7102329
Other Identifiers
ISSN
0012-6667,1179-1950
E-ISSN
1179-1950
DOI
10.1007/s40265-017-0705-5
